While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Core Viewpoint - The revised Local Coverage Determinations (LCDs) will no longer cover over 200 unproven skin substitutes, emphasizing the need for clinically effective and proven products in the wound care industry [1][2]. Group 1: Changes in LCDs - The number of separate treatment applications a patient can receive has increased from 4 to 8 [1]. - Treatment duration has been extended from 12 to 16 weeks [1]. - The Medicare Administrative Contractors (MACs) require well-powered, peer-reviewed clinical evidence for reimbursement [1]. Group 2: Industry Context - The wound care industry has seen a significant increase in spending, now exceeding $1 billion per month, which is over a 20-fold increase in the past five years [2]. - The MACs' actions are viewed as a corrective measure to address reimbursement abuses in the industry [2][3]. Group 3: Company Position - MiMedx Group, Inc. has two allografts, EPIFIX® and EPICORD®, on the list of covered products, positioning the company to benefit from the revised LCDs due to strong clinical evidence supporting its products [4]. - The company aims to restore order and good fiscal governance to the Medicare outpatient reimbursement system while ensuring patient access to clinically proven solutions [3]. Group 4: Company Overview - MiMedx is a leader in providing healing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider through relentless innovation [5].

MiMedx (MDXG) closed the last trading session at $6.93, gaining 20.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.33 indicates a 77.9% upside potential.The average comprises six short-term price targets ranging from a low of $11 to a high of $14, with a standard deviation of $1.03. While the lowest estimate indicates an increase of 58.7% from the current price level, the mo ...

MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating an ...

Earnings Announcement - The company will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024 [1] - The senior management team will host a webcast and conference call to review the results beginning at 4:30 p m Eastern Time on the same day [1] - The conference call can be accessed via webcast or by dialing 877-407-6184 for U S investors and 201-389-0877 for international investors with Conference ID 13748866 [1] - A replay of the webcast will be available for approximately 30 days on the company's website at www mimedx com following the conclusion of the event [1] Company Overview - The company is a pioneer and leader in helping humans heal, with over a decade of experience in assisting clinicians with chronic and hard-to-heal wounds [2] - It is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare [2] - The company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life [2] Contact Information - For investor relations inquiries, contact Matt Notarianni at 470-304-7291 or mnotarianni@mimedx com [3]

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: "Her Face Was Unrecognizable After an Explosion. A Placenta Restored It." The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the la ...

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professiona ...

Core Viewpoint - Ten former employees of MiMedx Group, Inc. have filed counterclaims against the company, alleging that MiMedx engaged in fraudulent practices to exploit Medicare and pressured employees to sell products without FDA approval [1][2]. Group 1: Allegations Against MiMedx - The counterclaims assert that MiMedx pressured healthcare providers to use medically unnecessary products on vulnerable patients, including wounded veterans and diabetics [2]. - Allegations include that MiMedx incentivized fraud against the U.S. government, particularly Medicare, through predatory sales practices [2]. - The claims reference a warning letter from the FDA regarding MiMedx's AXIOFILL product, indicating that the company misled its sales team about the product's marketability [2][3]. Group 2: Employee Experience and Company Response - Former employees claim they were compelled to sell a product that the FDA determined could not be marketed without prior approval, leading to their departure from the company [3]. - The counterclaims describe the original lawsuit from MiMedx as an intimidation tactic against employees who left due to the company's alleged misconduct [1].